Merging CHEMISTRY AND BIOLOGY TO BENEFIT THE LIVES OF PATIENTS

Adcentrx Therapeutics Closes $50 Million Series A Financing Round.

About Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Management team

Hui

Dr. Hui Li

President and CEO of Adcentrx Therapeutics

Dr. Hui Li is the President and CEO of Adcentrx Therapeutics with over 20 years of drug discovery and business development experience in the biotech and pharmaceutical industry.
Read More

Pia

Dr. Pia Challita-Eid

Head of Research at Adcentrx Therapeutics

Dr. Pia Challita-Eid serves as the Head of Research at Adcentrx Therapeutics. She brings over 20 years of experience in the biotechnology industry, contributing to the discovery and progression into the clinic of over 12 drug candidates including the FDA-approved product Padcev™.
Read More

ALEX

Dr. Alexander Chu-Kung

Head of development at Adcentrx Therapeutics

Alexander Chu-Kung is the head of development at Adcentrx Therapeutics. Prior to joining Adcentrx, Dr Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline.
Read More

Dr. Hui Li is the President and CEO of Adcentrx Therapeutics with over 20 years of drug discovery and business development experience in the biotech and pharmaceutical industry. Prior to founding Adcentrx, he was the CEO of Levena Biopharma, a subsidiary of Sorrento Therapeutics, focusing on antibody-drug conjugate (ADC) development. He also served as SVP of Business Development and General Manager of China Operations at Sorrento Therapeutics. During his time at Levena, he was responsible for developing a portfolio of site-specific ADC products and establishing a GMP production site to support clinical development of both internal and external ADC programs. Before Levena, he served as Executive Director of Business Development at PPD and Head of Business Development at its pre-clinical division BioDuro. Prior to joining PPD, he spent 10 years at Pfizer Global Research & Development, where he led a number of programs in the areas of oncology, diabetes, antiviral, and ophthalmology, which successfully progressed into clinical development.

Dr. Hui Li received his B.S. in Chemistry from Peking University and his Ph.D. in Organic Chemistry from University of California, San Diego.

Dr. Pia Challita-Eid serves as the Head of Research at Adcentrx Therapeutics. She brings over 20 years of experience in the biotechnology industry, contributing to the discovery and progression into the clinic of over 12 drug candidates including the FDA-approved product Padcev™.

Prior to joining Adcentrx, she served as Vice President, ADC Research at Levena Biopharm, a Sorrento Therapeutics company, where she led the preclinical ADC pipeline.  Previously, she held various positions with increasing responsibilities at Agensys Inc., an affiliate of Astellas Pharmaceuticals Inc., supporting the company’s pipeline portfolio including ADCs and Immuno-oncology candidates.  She led the molecular oncology initiatives, target identification and selection, therapeutic antibody discovery and engineering activities.  Dr. Challita-Eid began her career in academia as a faculty member at the University of Rochester Cancer Center focusing on cancer immunotherapy.

Dr. Challita-Eid received her B.S. and M.S. in Biology from the American University of Beirut, and her Ph.D. in Microbiology from the University of Southern California.  She conducted her post-doctoral training at the University of California, Los Angeles.

Alexander Chu-Kung is the head of development at Adcentrx Therapeutics.  Prior to joining Adcentrx, Dr Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline. 

Before joining Levena Biopharma, Dr Chu-Kung spent more than decade at Abbvie, most recently as a principal scientist.  In this role he oversaw process development, tech transfer, CMO interaction and scale-up for both small molecule and biologic therapeutics.

Alexander holds a Ph.D. degree in Chemical Engineering from University of California, Santa Barbara and a B.S. degree in chemical engineering from Northwestern University.

Alexander Chu-Kung is the head of development at Adcentrx Therapeutics.  Prior to joining Adcentrx, Dr Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline. 

Before joining Levena Biopharma, Dr Chu-Kung spent more than decade at Abbvie, most recently as a principal scientist.  In this role he oversaw process development, tech transfer, CMO interaction and scale-up for both small molecule and biologic therapeutics.

Alexander holds a Ph.D. degree in Chemical Engineering from University of California, Santa Barbara and a B.S. degree in chemical engineering from Northwestern University.